E.E. Geduld’s Acceleron Pharma XLRN Stock Holding History

E.E. Geduld’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-6,500	Closed	-$206K	–	286
2015 Q2	$206K	Hold	6,500	–	–	0.13%	172
2015 Q1	$247K	Hold	6,500	–	–	0.16%	141
2014 Q4	$253K	Buy	+6,500	New	+$227K	0.14%	124
2014 Q3	–	Sell	-10,000	Closed	-$340K	–	287
2014 Q2	$340K	Buy	10,000 +2,500	+33%	+$83.6K	0.21%	120
2014 Q1	$259K	Buy	+7,500	New	+$338K	0.14%	157

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return

PVMCI

Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

E.E. Geduld's XLRN Position: Q3 2015 in Review

E.E. Geduld sold out of Acceleron Pharma (XLRN) in Q3 2015, closing a stake of 6,500 shares — an estimated $206K sold.

E.E. Geduld first reported a position in XLRN in Q1 2014 and held it in 5 quarters. The position peaked at $340K in Q2 2014. 111 funds tracked by Wall St. Rank hold XLRN as of Q3 2015.

E.E. Geduld reported no remaining Acceleron Pharma position as of Q3 2015 after selling out during the quarter.
E.E. Geduld sold 6,500 Acceleron Pharma shares in Q3 2015, an estimated $206K.
E.E. Geduld first reported a position in Acceleron Pharma in Q1 2014 and held it in 5 quarters.
E.E. Geduld's Acceleron Pharma position peaked at $340K in Q2 2014.
111 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2015.

Based on E.E. Geduld's 13F filing for Q3 2015, filed 6 Nov 2015.